Anticoagulation with argatroban for elective percutaneous coronary intervention: Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters

Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2011, Pages 805-818

  Akimoto, Kei ^a   Klinkhardt, Ute ^b   Zeiher, Andreas ^b   Niethammer, Margit ^c   Harder, Sebastian ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

anticoagulation; argatroban; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; ECARIN; HEPARIN; MEIZOTHROMBIN; PROTHROMBIN; THROMBIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; COMPARTMENT MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN CLEAVAGE;

AGED; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOVASCULAR PROCEDURES; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PIPECOLIC ACIDS;

EID: 79955817183     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372627     Document Type: Article

References (22)

1. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997 ; 23: 503-516 (Pubitemid 28114046)
2. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005 ; 353: 1028-1040 (Pubitemid 41262337)
3. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 ; 103: 1838-1843 (Pubitemid 32328395)
4. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced throm-bocytopenia. Catheter Cardiovasc Interv. 2002 ; 57: 177-184
5. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000 ; 20: 318-329 (Pubitemid 30140749)
6. Yeh RW, Jang IK. Argatroban: update. Am Heart J. 2006 ; 151: 1131-1138 (Pubitemid 43866614)
7. Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis. 2004 ; 18: 31-37 (Pubitemid 40361646)
8. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ, et al. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. Blood Coagul Fibrinolysis. 2008 ; 19: 401-4044
9. Cox DS, Kleiman NS, Boyle DA, et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol. 2004 ; 44: 981-990 (Pubitemid 39096813)
10. Roessig L, Genth-Zotz S, Rau M, et al. Argatroban anticoagulation for PCI: The E04 European Multi-Center Study. Int J Cardiol. 2010 ;:
11. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004 ; 43: 963-981 (Pubitemid 39602013)
12. Fenyvesi T, Jorg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb. 2002 ; 32: 174-179 (Pubitemid 37449310)
13. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res. 2008 ; 123: 396-403
14. al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost. 2004 ; 2: 1395-1401 (Pubitemid 40186137)
15. Wählby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS Pharm Sci. 2002 ; 4 :
16. Swan S, Peter J, Lambrecht L, Hursting M. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy. 2000 ; 20: 756-770 (Pubitemid 30457355)
17. Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost. 2002 ; 8: 217-224
18. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. 1995 ; 75: 559-562
19. Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis. 2005 ; 16: 251-257 (Pubitemid 40705046)
20. Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica. 2003 ; 88: 547-554 (Pubitemid 36648444)
21. Harder S, Merz M, Klinkhardt U, et al. Influence of argatroban on coagulation parameters in heparin-induced thrombocytopenia patients after cardiothoracic surgery. J Thromb Haemost. 2007 ; 9: 1982-1984 (Pubitemid 47288963)
22. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost. 2004 ; 91: 1137-1145 (Pubitemid 38821270)